Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
    • Internet & Telecom
  • Toggle search form
  • [Research] Celltrion (068270) – Shinhan Securities | North American New Product Penetration · 2030 Pipeline · New Drug Cycle / 2026-07-28 Research
  • [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM Demand · AI Accelerator Diversification · Profitability / 2026-01-21 Research
  • [Research] Alteogen (196170) – Hana Securities | Target Price Adjusted on Royalty Structure & Deal Assumptions · Deal Acceleration Starts in 2026 / 2026-01-22 Research
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | FC-BGA CAPEX Expansion · Price Hikes · 2028F Forward Valuation / 2026-05-06 Research
  • [Research] Samsung Electronics (005930) – Kiwoom Securities | Mobile Rush Orders · HBM4 Market Share Gains · Cache Compression Technology / 2026-03-30 Research
  • [Research] Samsung Electronics (005930) – Mirae Asset | LPDDR5X Price Hikes · ASP Trajectory Upgrades · Target Price Upgrade / 2026-05-20 Research
  • [Research] Samsung Electronics (005930) – Shinhan | Memory Excess Demand · DS Earnings Surge · Shareholder Return Expectations / 2026-04-21 Research
  • [Research] Alteogen (196170) – Shinhan Securities | First UK Patent Ruling Favors Merck · Positive Read-across to Global Disputes · Pipeline Out-Licensing Ahead / 2026-02-23 Research

[Research] Samsung Electronics (005930) – Mirae Asset | Shareholder Return · FCF Expansion · Valuation Undervaluation / 2026-06-01

Posted on 6월 1, 20268월 25, 2026 By ksb220805@gmail.com

Brokerage : Mirae Asset Securities

Analyst : Younggun Kim

Investment Rating : BUY (Maintained)

Target Price : KRW 550,000 (Maintained)

Core Momentum : Upside potential driven by expected massive special dividends from the 2024–2026 FCF settlement, mid-to-long term shareholder return expansion backed by robust FCF generation, and deeply undervalued multiples.

📊 1. [Valuation & Key Financial Metrics]

  • Rating & Target Price: BUY maintained with a Target Price of KRW 550,000 (73.5% upside potential from May 29, 2026 closing price of KRW 317,000)
  • Valuation Multiples:
    • Target Price is derived by applying a 2026F P/E multiple of 12.0x
    • Current share price implies a 2026F P/E of 6.9x and P/B of 2.8x (2027F P/E 5.0x, P/B 1.9x), representing an absolute undervaluation against fundamental growth
  • Key Financial Metrics & Forecasts (2024 ~ 2028F):
    • 2024: Revenue KRW 300.87T, OP KRW 32.73T, Net Profit KRW 33.62T, EPS KRW 4,950, ROE 9.0%, P/E 10.7x, P/B 0.9x, Div. Yield 2.7%
    • 2025: Revenue KRW 333.61T, OP KRW 43.60T, Net Profit KRW 44.26T, EPS KRW 6,564, ROE 10.8%, P/E 18.3x, P/B 1.9x, Div. Yield 1.4%
    • 2026F: Revenue KRW 708.85T, OP KRW 371.44T (vs. consensus KRW 351.66T), Net Profit KRW 305.78T, EPS KRW 45,841, ROE 52.7%, P/E 6.9x, P/B 2.8x, Div. Yield 3.7%
    • 2027F: Revenue KRW 909.71T, OP KRW 499.53T, Net Profit KRW 424.79T, EPS KRW 63,891, ROE 46.8%, P/E 5.0x, P/B 1.9x, Div. Yield 5.2%
    • 2028F: Revenue KRW 981.70T, OP KRW 512.10T, Net Profit KRW 460.68T, EPS KRW 69,289, ROE 36.7%, P/E 4.6x, P/B 1.5x, Div. Yield 5.5%

🚀 2. [Market Opportunities & Business Outlook]

  • 2024–2026 Shareholder Return Settlement & Special Dividend Expectations:
    • Under the policy to return 50% of 3-year FCF (annual fixed dividend of KRW 9.8T with surplus distributed as special dividend), significant special dividends are anticipated as cumulative FCF is projected to exceed targets.
    • Assuming a minimum payout ratio of 25% for dividend income separate taxation, scenario analysis (100% cash vs. 30% buyback/cancellation + 70% cash, including/excluding M&A) yields estimated dividend yields of 3.7–6.5% for common shares and 5.8–10.1% for preferred shares.
    • Preferred shares trade at a 36% discount to common shares, wider than the historical average of 22%, presenting room for discount contraction ahead of the March 2027 special dividend resolution.
  • Long-term FCF Surge & Upward Revision of Return Policy:
    • Past fixed dividends (KRW 9.6–9.8T annually) assumed a 3-year cumulative FCF of KRW 60T; however, with annual FCF projected to exceed KRW 200T starting in 2026, the fixed dividend amount or the 50% FCF return ratio could be revised upward.
  • Earnings Forecasts:
    • 2Q26F Operating Profit estimated at KRW 89T (above market consensus of KRW 88T)
    • 2026F Operating Profit estimated at KRW 371T (above market consensus of KRW 358T)

📝 Editor’s Comment (Perspective)

The analyst views Samsung Electronics not merely as a business undergoing an earnings recovery, but as a premier cash-generating enterprise capable of delivering substantial shareholder returns through massive Free Cash Flow (FCF) expansion. This perspective places primary emphasis on the upcoming 2024–2026 shareholder return settlement and the high probability of an upgraded payout structure for future cycles as key catalysts for valuation re-rating.

To determine whether this investment thesis materializes, key verification checkpoints include the actual magnitude of annual FCF generation in 2026, the resolution of special dividends and share cancellations in March 2027, and the potential upward revision of base dividends or payout ratios in the subsequent 3-year shareholder return policy. These developments can be tracked through upcoming quarterly IR materials, annual business reports, and official regulatory filings on DART/KRX.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

글 탐색

Previous Post: [Research] SK hynix (000660 / SKHY) – Mirae Asset | LTA · HBM Demand · Valuation Re-rating / 2026-05-27
Next Post: [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · PHLX Inclusion · Valuation Re-rating / 2026-06-01

Related Posts

  • [Research] SK hynix (000660 / SKHY) – Hana | Memory Pricing · Cash Flow · Shareholder Returns / 2026-01-30 Research
  • [Research] Samsung SDI (006400) – Kiwoom Securities | Near-Term Sluggishness but Intact Momentum · 4Q26 Turnaround · Solid-State Pipeline / 2026-02-03 Research
  • [Research] Samsung Electronics (005930) – Hanwha Investment & Securities | 5-Year LTA · HBM4 Pricing · Shareholder Return / 2026-07-31 Research
  • [Research] SK Telecom (017670 / SKM) – Yuanta Securities | Core Profit Normalization · SK Hyper Launch · Unpriced AIDC Value / 2026-08-06 Research
  • [Research] LigaChem Biosciences (141080) – IBK Securities | Enhertu Resistance · Clinical Readouts · Tech Transfer / 2025-11-27 Research
  • [Research] Samsung Electronics (005930) – Eugene Investment & Securities | Memory Pricing Leverage · Supplier-Favorable Dynamics · Upward Forecast Revisions / 2026-01-09 Research
  • [Research] Samsung SDI (006400) – Kyobo Securities | Gradual Loss Narrowing · Solid-State Battery Development Pipeline · Robotics Partnerships / 2026-02-03 Research
  • [Research] LIG D&A (079550) – SK Securities | Modern Warfare Leader · Limited Global CapEx · Multiple Re-rating / 2026-04-07 Research
  • [Research] Samsung Electronics (005930) – Daishin Securities | Memory ASP Surge · Mobile Demand · Non-Memory Loss Contraction / 2026-04-07 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Big Tech Backlogs · Memory Supply Tightness · Earnings Growth / 2026-07-14 Research
  • [Research] Samsung SDI (006400) – IBK Securities | Fully Booked North America ESS Expected · European IAA Benefits · 1Q Earnings Resilience / 2026-04-02 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Readouts · Pipeline Valuation · SOTP / 2026-01-26 Research
  • [Research] Samsung Electronics (005930) – Hana Securities | Memory Pricing · LTA Structure · Earnings Upward Revision / 2026-04-08 Research
  • [Research] ABL Bio (298380) – Kiwoom Securities | ABL301 Deprioritization · ABL001 Valuation · Grabody B Validity / 2026-02-02 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme